Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Drug Proves Helpful for Treating Long-Term Insomnia

22.10.2003


Researchers at Duke University Medical Center and elsewhere have completed the first large-scale study demonstrating sustained efficacy of a medication to treat insomnia for a period of six months.



Eszopiclone (trade name Estorra), was administered nightly to patients with chronic insomnia and led to significant improvement in patients’ ability to fall asleep and stay asleep and in the quality of their sleep without any evidence of a loss of effect over time, the researchers said. Prior to this study, the longest large-scale, placebo-controlled study of a sleep medication for insomnia lasted five weeks.

The data further demonstrate that improvements in sleep were associated with consistent improvements in the patients’ ratings of their capacity to function well during the day, said the researchers. Impairments in daytime function are one aspect of chronic insomnia, and the new study represents the first time any sleep medication has been shown to consistently improve all of the components that define insomnia, they said.


Insomnia is the perception of inadequate or poor-quality sleep that is accompanied by significant distress or impaired function. It is considered to be chronic if it occurs on most nights and lasts a month or more, according to the National Institute of Health.

"I believe that this study is a milestone for research into insomnia treatments," said Andrew Krystal, M.D., lead study author and associate professor of psychiatry and director of the Sleep Research Laboratory and Insomnia Clinic at Duke. "It greatly extends the period of time that a medication has been definitively shown to help people suffering from insomnia and it establishes that studies of longer-term drug treatment of insomnia are not only feasible but can be safely performed."

The research findings appear in the Nov. 1, 2003, issue of the journal Sleep.

The researchers randomized 788 patients aged 21 to 69 into a six-month, double-blind, placebo-controlled study of three-milligram nightly doses of eszopiclone to treat their insomnia. Participants were required to meet the standard criteria used to make the clinical diagnosis of primary insomnia and to report, on average, less than six-and-a-half hours of sleep per night, or that it took at least 30 minutes to fall asleep for at least one month prior to being screened for the study.

According to Krystal, the results provide the first step toward establishing an empirical base to guide the long-term treatment of chronic insomnia with medication. The findings suggest that eszopiclone has the potential to provide doctors with a treatment option that could be prescribed for patients who require longer-term treatment. The data demonstrate that eszopiclone is safe and could be helpful. By opening the door for future studies of longer-term treatments for insomnia, this study represents an important step in the evolution toward improving treatment options for patients with chronic insomnia, he added.

"The fact that eszopiclone improved not only the difficulties in sleep that patients experience but also their reports of problems they typically experience during their waking hours, suggests the need for a change in our perspective," Krystal said. "The idea that effective treatment should address the entire spectrum of difficulties experienced by patients with insomnia is really a new way of thinking for the field."

An estimated 2.5 percent of Americans take sleep medications for insomnia in any given year, the researchers report. Of these, about 23 percent take such medications on a nightly basis for four months or longer. However, clinical research studies have examined the use of such drugs for an average use of one week. The problem with this, the researchers say, is that long-term drug treatment is being carried out without the existence of research supporting that long-term use is safe or effective in adults.

Nearly 60 percent of American adults surveyed about their sleep habits say they experience sleep problems more than a few times each week, according to the National Sleep Foundation. In their 2003 "Sleep in America" poll, the group found that insomnia is the most common sleep problem and that only one in eight older adults say their problems have been diagnosed.

Of the many people who report sleep problems, 20 to 36 percent report that their problem lasted for more than one year. Thus, the researchers say, it is not surprising that so many people are using sleep medications for long periods of time.

Research funding was supported by Sepracor, Inc., the manufacturer of eszopiclone, a compound currently under review by the Food and Drug Administration.

Krystal has previously designed and conducted other studies for Sepracor and has served on an advisory board there.

Other authors on the study include James Walsh, Ph.D., of St. John’s/St. Luke’s Hospital and St. Louis University; Eugene Laska, Ph.D., of Nathan Klein Institute for Psychiatric Research and New York University School of Medicine; Judy Caron, Ph.D., of Sepracor, Inc. in Marlborough, Mass.; and David Amato, Ph.D., Thomas Wessel, Ph.D., and Thomas Roth, Ph.D., all of Henry Ford Sleep Disorders Center in Detroit, Mich.

Tracey Koepke | dukemed news
Further information:
http://dukemednews.org/news/article.php?id=7126

More articles from Health and Medicine:

nachricht Chances to treat childhood dementia
24.07.2017 | Julius-Maximilians-Universität Würzburg

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: 3-D scanning with water

3-D shape acquisition using water displacement as the shape sensor for the reconstruction of complex objects

A global team of computer scientists and engineers have developed an innovative technique that more completely reconstructs challenging 3D objects. An ancient...

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

Ultrathin device harvests electricity from human motion

24.07.2017 | Power and Electrical Engineering

Scientists announce the quest for high-index materials

24.07.2017 | Materials Sciences

ADIR Project: Lasers Recover Valuable Materials

24.07.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>